The MERS coronavirus—MERS stands for “Middle East respiratory syndrome”—causes severe respiratory diseases with a high mortality rate. To date, there is neither a vaccine nor a specific treatment. The safety, immunogenicity and optimal dosing regimen of the MVA-MERS-S vaccine candidate developed at the DZIF have now been investigated in a phase Ib study in healthy individuals who were previously infected with the related coronavirus SARS-CoV-2.
Vaccine against the MERS coronavirus tested as safe and effective in phase Ib clinical trial
